MaxCyte, Inc. Poster Presentation on MCY-M11 at ASCO 2020 (8406M)
May 14 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8406M
MaxCyte, Inc.
14 May 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte to Present Poster Presentation on MCY-M11
at ASCO 2020 Annual Meeting
Gaithersburg, Maryland - 14 May 2020: MaxCyte (LSE: MXCT), the
global clinical-stage cell-based therapies and life sciences
company, announces that clinical data from the first three cohorts
of the ongoing Phase I dose-escalation trial demonstrating safety
of MCY-M11 and feasibility of one-day manufacturing will be shared
at the American Society of Clinical Oncology's (ASCO) upcoming
annual meeting. The ASCO20 Virtual Scientific Program will be held
May 29-31, 2020.
The Poster Discussion presentation, entitled Feasibility and
preliminary safety and efficacy of first-in-human intraperitoneal
delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected
into peripheral blood mononuclear cells, for ovarian cancer and
malignant peritoneal mesothelioma, will be available in the
Developmental Therapeutics: Immunotherapy session, which can be
accessed on demand beginning at 8 a.m. ET on Friday, May 29,
2020.
MCY-M11 is a wholly-owned, non-viral, mRNA-based cell therapy
candidate manufactured using un-manipulated peripheral blood
mononuclear cells. It is under development for the treatment of
ovarian cancer and peritoneal mesothelioma. The ongoing study so
far demonstrates both the safety and of MCY-M11 as well as the
feasibility of one-day manufacturing and intraperitoneal delivery
of our cell product.
As previously announced, dosing began in October 2019 in the
third cohort in MaxCyte's Phase I dose-escalation trial with
MCY-M11 and there have been no dose-limiting toxicities or related
serious adverse events observed in the three completed cohorts. A
fourth dosing cohort commenced in March 2020 as expected.
Preliminary clinical results for the trial are expected to be
announced in H2 2020. Clinical development of MCY-M11 continues now
under the auspices of MaxCyte's subsidiary CARMA Cell
Therapies(TM). No new material information will be included in the
ASCO presentation .
For more information about the ASCO20 Virtual Scientific Program
and a link to the abstract, please visit:
https://meetinglibrary.asco.org/record/185279/abstract .
About CARMA Cell Therapies
Through its wholly owned subsidiary, CARMA Cell Therapies,
MaxCyte is facilitating advancement of novel mRNA-based cell
therapies for cancer and other diseases with serious unmet needs.
MaxCyte has developed CARMA, a novel and proprietary platform for
the development of non-viral, human messenger RNA (mRNA)-based,
chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected
immune cell therapies. CARMA [derived from CAR mRNA] utilizes
MaxCyte's Flow Electroporation(R) technology for highly efficient,
non-viral, delivery of one or more mRNA(s) into un-manipulated
peripheral blood mononuclear cells (PBMCs) or isolated immune cells
such as T- or NK-cells. CARMA offers the potential for a safer cell
therapy, as a result of transient expression of receptor(s) and a
non-viral delivery approach. Together, CARMA and MaxCyte's
EXPERT(R) family of instruments also offer the potential for a
significantly streamlined, scalable, and cost-effective GMP
manufacturing process without the complexity of virus-based
products. At the start of 2020, MaxCyte established CARMA Cell
Therapies as a wholly owned subsidiary to facilitate independent
investment and new partnerships to advance the CARMA platform.
MaxCyte has retained Locust Walk, a global life science strategic
advisory and transaction firm. The Company expects CARMA to be
self-funded by end of 2020. For more information, visit
https://www.maxcyte.com/carma-cell-therapies/ .
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 100 cell therapy programmes, with more than 70 licensed
for clinical use, and the Company has now entered into ten
clinical/commercial license agreements with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (AIM:MXCT) and is
headquartered in Gaithersburg , Maryland, US. For more information, visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.
Chris Welsh com
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGZGMKZFMGGZZ
(END) Dow Jones Newswires
May 14, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024